Updated 07:15 GMT, 18 Nov 2026 SPX 7,340.53 -1.03% NDX 27,001.78 -0.72% VIX 25.46 +11.13% GOLD 3,772.20 -2.38% CL 83.98 -2.36% BTC 64,721.99 -0.26%
NAS100 27,002 −0.72% S&P 7,341 −1.03% GOLD $3,772 −2.38% BTC $64,722 −0.26% VIX 25.46 +11.13% latest tape · as of 07:15 UTC
The Screen · Consumer Cyclical · Personal Services

Andersen Group Inc.

ANDG · the NYSE · USD · Market cap $736M · 2,271 employees

Andersen Group Inc.

FAIL · Does not pass the screen
63.08 USD

Price as of 17 Nov 2026Daily close, not a live quote

Screened 2026-11-17 · the tape above runs as of 07:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price63.08 USD at the 17 Nov 2026 close
  • Our value readOvervalued vs our fair value, as of 17 Nov 2026
  • Our regime readAccumulation, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • Last reviewed17 Nov 2026 (1 day ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: $44.10 to $62.81, base estimate $53.12 (screen dated 2026-11-17).

Current read
Accumulation ?
Overvalued · screened 2026-11-17
  • Trend Accumulation
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options no verdict drawn today, left as found
  • Ethical does not pass the values gate
Price63.08 USD
Fair value53.12
Ethical score70.0/100
Value readOvervaluedas of 17 Nov 2026
Our investment reviews on this name
2026-07-02Read Accumulation37.78+67.0% to today ✓First review on file: Accumulation

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its accumulation label.

Andersen Group Inc. holds its Accumulation at $63.08. Consolidating, no directional conviction, held for 1 days.

As held on the ledger · 2026-11-17
PhaseAccumulation
Quantitative stateConsolidating, no directional conviction, held for 1 days
Price at the screen$63.08
Valuation121.44 trailing · 23.93 forward price to earnings
Values screenFAIL · score 70.0
The Workings

Five Screens, Shown in Full

Does not pass. Debt ratio

TestFigureLimitWhat it meansStatus
Business activity Permissible Core business clean Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
Debt load 81.49% Below 33% Interest-bearing debt is 81.5% of its assets, above the one-third ceiling the screen allows. Fail
Interest-bearing cash 1.45% Below 33% Cash held in interest-bearing accounts and securities is 1.4% of assets, under the one-third limit. Pass
Receivables 66.12% Below 49% Money owed to the company is 66.1% of assets, above the 49% limit. Fail
Revenue purity 0.50% Below 5% Only 0.5% of revenue comes from non-compliant sources, under the 5% line. Pass

Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.

The Ethical Read

Why It Falls Short, in Plain English

Andersen's business is in a permissible area, but its interest-bearing debt is about 81% of the company, well over the ~33% line, so it does not pass on the financial screens. Its receivables are also high.

Read as at 2026-11-17. It updates when the underlying figures move, and past reads are kept below.

Follow this verdict

Get an email when ANDG's ethical verdict changes

Today ANDG does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Our analysis reads Overvalued vs our fair value, as of 17 Nov 2026: it trades above our $53.12 fair value estimate, 23.70% revenue growth.

How a fair value is estimated: discounted cash flow (DCF).

44.10Conservative53.12Base case62.81Growth case 63.08Price

Fair value range in USD, drawn from the 2026-11-17 screen. The gold marker is the market price at the same screen. The price runs 18.8% above the base estimate.

The Street's Range
49.00Street low 56.00Street average 66.00Street high 63.08Price

Third-party analyst targets: 7 covering, consensus Buy. The average target sits −11% from the screen price.

Reading the gap · Both our model and the Street see limited upside at this price.

Price History & Projections

Where our models see it going: fair-value estimate $53.12, with a range of $44.10 to $62.81, dated to the 2026-11-17 screen.

Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.

The Business, in Plain Words

Why it gives us pause

At 23.9x forward earnings, the price already runs ahead of the business. It trades 19% above our $53.12 fair value, so you would be buying at a premium, not a discount.

The fundamentals · plain-English read
Forward P/E23.9xfairly priced for its growth rate
Trailing P/E121.4xexpensive: the price assumes strong growth ahead
EPS, trailing0.45
EPS, forward2.28
Revenue growth+23.7%strong top-line growth
Profit margin4.7%barely profitable
Return on equity-67.1%not currently earning a positive return on equity
FCF yield2.26%
Debt to equity13.17heavy leverage: higher risk if revenue softens
Current ratio2.19comfortably covers its short-term bills
Short interest, float0.21%
52-week range18.12 - 57.62
Market cap$736M
Employees2,271

Another profit measure, before interest, tax and non-cash costs: EBITDA.

The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it carries a real debt load, which raises the stakes if revenue slips.

Plain-English interpretation of our own screen data. Analysis, not advice.

Where & How to Trade

ANDG trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-12 Accumulation $65.84 +0.1% Entry 18

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading overbought. Our forward projection puts the odds of a 10% gain over the next month near 53%. The street (6 analysts) rates it buy, with a mean price target of $40. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-11 Accumulation $65.77 0.0% Entry 17

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading overbought. Our forward projection puts the odds of a 10% gain over the next month near 53%. The street (6 analysts) rates it buy, with a mean price target of $40. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-10 Accumulation $65.80 +1.2% Entry 16

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 1.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading overbought. Our forward projection puts the odds of a 10% gain over the next month near 53%. The street (6 analysts) rates it buy, with a mean price target of $40. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-09 Accumulation $65.00 +0.0% Entry 15

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading overbought. Our forward projection puts the odds of a 10% gain over the next month near 53%. The street (6 analysts) rates it buy, with a mean price target of $40. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-08 Accumulation $65.00 +0.0% Entry 14

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading overbought. Our forward projection puts the odds of a 10% gain over the next month near 53%. The street (6 analysts) rates it buy, with a mean price target of $40. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-07 Accumulation $65.00 -1.9% Entry 13

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 1.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A. Technically it is momentum reading overbought. Our forward projection puts the odds of a 10% gain over the next month near 53%. The street (6 analysts) rates it buy, with a mean price target of $40. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-06 Accumulation $66.27 -1.8% Entry 12

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 1.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A. Technically it is momentum reading overbought. Our forward projection puts the odds of a 10% gain over the next month near 53%. The street (6 analysts) rates it buy, with a mean price target of $40. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-05 Accumulation $67.46 +14.4% Entry 11

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 14.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A. Technically it is momentum reading overbought. Our forward projection puts the odds of a 10% gain over the next month near 53%. The street (6 analysts) rates it buy, with a mean price target of $40. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-27 Accumulation $58.95 +3.7% Entry 10

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 3.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A. Technically it is momentum reading overbought. Our forward projection puts the odds of a 10% gain over the next month near 53%. The street (6 analysts) rates it buy, with a mean price target of $40.

2026-10-12 Accumulation $56.82 +4.0% Entry 9

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 4.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A. Technically it is momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 53%. The street (6 analysts) rates it buy, with a mean price target of $40.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

Latest News · What the Market Is Reading on ANDG

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in ANDG's Space

Screened names in the same industry · explore each on its own page.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $36.65 +0.3% · $1,003 +0.3%
2 months $28.25 +30.1% · $1,301 +30.1%
3 months $24.53 +49.8% · $1,498 +49.8%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever ANDG does next, these words stay.

Andersen Group Inc. · ANDG · Accumulation · $63.08
Recorded 2026-11-17 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.